|
Aug 7
|
Knight Therapeutics Q2 Net Loss Widens, Revenue Rises
|
|
Aug 7
|
Knight Therapeutics Reports Second Quarter 2025 Results
|
|
Aug 5
|
Update on Knight Therapeutics: Applies for Mexican Approval to Market Parkinson's Disease Treatment
|
|
Aug 5
|
Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico
|
|
Aug 5
|
Knight Therapeutics, Incyte Expand Relationship to Distribute Additional Medicines in Latin America
|
|
Aug 4
|
Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America
|
|
Aug 1
|
Notice of Knight Therapeutics' Second Quarter 2025 Results Conference Call
|
|
Jul 31
|
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil
|
|
Jul 24
|
TSX Growth Companies With High Insider Ownership For July 2025
|
|
Jul 18
|
Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada
|